Skip to search formSkip to main contentSkip to account menu

cyclophosphamide/doxorubicin/prednisone/rituximab/vincristine

Known as: Rituximab/Cyclophosphamide/Doxorubicin/Prednisone/Vincristine, R-CHOP Regimen, Rituxan/CHOP 
An abbreviation for a chemotherapy combination that is used to treat non-Hodgkin lymphoma and mantle cell lymphoma and is being studied in the… 
National Institutes of Health

Related topics

Related topics

8 relations
CyclophosphamideDoxorubicinDoxorubicin HydrochlorideLymphoma, Non-Hodgkin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study
Background: Minimal residual disease (MRD) status reflects treatment efficacy and may predict prognosis after first-line therapy… 
Highly Cited
2011
Highly Cited
2011
Accurate Classification of Diffuse Large B-Cell Lymphoma into Germinal Center and Activated B-Cell Subtypes Using a Nuclease Protection Assay on Formalin-Fixed, Paraffin-Embedded Tissues
Classification of diffuse large B-cell lymphoma (DLBCL) into cell-of-origin (COO) subtypes based on gene expression profiles has… 
Highly Cited
2009
Highly Cited
2009
High‐dose Ara‐C and beam with autograft rescue in R‐CHOP responsive mantle cell lymphoma patients
Mantle cell lymphoma (MCL) has a dismal outcome when treated with conventional chemotherapy. This single arm phase 2 study… 
2009
2009
Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B‐cell lymphoma
Bortezomib demonstrated promising activity in lymphomas. The authors conducted a randomized phase 2 trial of frontline rituximab… 
Highly Cited
2007
Highly Cited
2007
Early Response Assessment Using 3′-Deoxy-3′-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma
Purpose: To evaluate 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography (FLT-PET) for early monitoring response of… 
Highly Cited
2004
Highly Cited
2004
Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of…
PURPOSE To evaluate the safety and efficacy of liposomal doxorubicin (Myocet; Medeus Pharma Ltd, Herts,UK) when substituted for… 
Highly Cited
2000
Highly Cited
2000
The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
The incidence of non-Hodgkin's lymphoma has been increasing at a rate of 4% per year since 1950; more than 62,000 cases will be… 
Highly Cited
2000
Highly Cited
2000
Chemotherapy for the treatment of patients with primary high grade gastric B‐cell lymphoma of modified Ann Arbor stages IE and IIE
Surgical intervention and combined modality treatment including radiation and chemotherapy have been studied widely in patients… 
1998
1998
Blastic NK‐cell lymphoma expressing terminal deoxynucleotidyl transferase with Homer–Wright type pseudorosettes formation
Aims: Rosette‐forming malignant lymphoma is very rare. We report a blastic NK‐cell lymphoma expressing terminal deoxynucleotidyl… 
1993
1993
Medulloblastoma in adults: survival and prognostic factors.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)